Wisconsin Capital Management LLC Has $5.44 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Wisconsin Capital Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 5.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 63,179 shares of the company’s stock after selling 3,850 shares during the quarter. Novo Nordisk A/S comprises 3.0% of Wisconsin Capital Management LLC’s investment portfolio, making the stock its 12th largest holding. Wisconsin Capital Management LLC’s holdings in Novo Nordisk A/S were worth $5,435,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Albion Financial Group UT increased its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the last quarter. Sound Income Strategies LLC raised its holdings in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares in the last quarter. Hager Investment Management Services LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $46,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $47,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NVO. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Down 2.1 %

Shares of NVO opened at $68.00 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a 50-day simple moving average of $81.89 and a 200-day simple moving average of $97.68. Novo Nordisk A/S has a 52 week low of $66.81 and a 52 week high of $148.15. The firm has a market capitalization of $305.16 billion, a P/E ratio of 20.67, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.